Group items tagged

The purpose of this FOA is the rapid and efficient translation of innovative laboratory research findings into therapies, devices or other resources for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians will focus on generating preclinical data that will lead to the development of biological interventions, such as gene therapy, cell-based therapy, pharmacological approaches, and/or medical devices. The ultimate goal of this program is to make technological, biological and pharmacological resources available to clinicians and their patients.

The foundation is accepting applications from investigators who are conducting studies designed to advance the understanding of specific therapeutic applications of massage, improve public perceptions of and attitudes toward massage therapy, and increase the role of massage therapy in healthcare delivery.

This FOA requests research applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome.  The overarching emphasis is on the acquisition of knowledge that can be translated into new, enhanced, or tailored therapies for co-occurring conditions in individuals with Down syndrome. Applications should focus on delivering better healthcare outcomes and should seek solutions that are effective and deliverable. Research is needed to develop or test new and innovative adaptations of current drugs, interventions, and therapies for the treatment and management of co-occurring conditions in Down syndrome. These therapies should be implementable and sustainable in clinical settings beyond the research environment. Research applications may address a particular co-occurring condition at a particular stage of development or across the lifespan in people with Down syndrome. Outcomes research and health services research related to Down syndrome are also responsive to this FOA. Because some aspects of this research area are new for the trans-NIH scientific community, there will likely be a need to obtain preliminary data or conduct early-stage clinical trial preparatory activities before moving to a full-scale project. The Exploratory/Developmental Phased Innovation (R61/R33) grant mechanism is appropriate for this purpose. It provides opportunities for creating, developing, and strengthening new and necessary collaborations, as well as acquisition of preliminary data, and allows for milestone-driven research, supporting a phased research project with a stepped approach for implementation of a clinical trial.

Significant advances in the understanding of the pathophysiology and molecular biology of multiple myeloma have identified numerous molecular targets for therapeutic intervention. Immunotherapeutic approaches (e.g., Daratumumab and Elotuzumab) have established themselves in the armamentarium for multiple myeloma, and ongoing adoptive cell therapy trials provide encouraging signs of clinical activity. As immune-based therapeutic agents continue to advance their way through the clinic, there is a critical need for increased understanding of the role that the immune system plays in myeloma disease biology, disease progression, and therapeutic response and resistance. The knowledge developed through this RFP will be critical to fully developing precision immunotherapy for the treatment of myeloma. To that end, MMRF is seeking applications for its MMRF Research Fellows Awards. Through the program, the foundation will support research projects focused on the immune biology of multiple myeloma and precursor disease; rational immune therapy and the immunological basis of response and resistance; next generation adoptive cell therapies; and next generation liquid biopsies and diagnostics.

The Foundation for Physical Therapy Research is dedicated to improving the quality and delivery of patient care by providing support to emerging investigators working to promote scientifically based and clinically relevant research related to the effectiveness of physical therapist practice. To that end, the foundation is accepting applications for its Goergeny High Impact/High Priority Research Grant. Through the program, a grant of up to $360,000 over three years ($240,000 over two years, with the possibility of a competitive third-year renewal) will be awarded to a physical therapist investigator focused on the role of physical therapy in the prevention of secondary health conditions, impairments of body structures and functions, activity limitations, and/or participation restrictions.

The purpose of this FOA is to solicit applications for an Epilepsy Center without Walls (CWOW) focused on collaborative preclinical and clinical research to prepare for translational and clinical development of disease modifying or prevention therapies for epilepsy. An additional goal is to develop community partnerships and community resources to advance development of such therapies.   

Despite clear progress made during the last 15 years on cellular transplantation for T1D, the most recent results demonstrate a long term limited viability of engrafted islets and, as a result, limited insulin independence under different novel modalities of immunosuppressive (IS) regimens tested.  In addition, even the most innovative IS regimens required for transplant survival still have significant immediate side effects and long-term safety is uncertain. These problems together with the scarcity of donor organs and the complexity of transplants mandates a renewed emphasis on the investigation of novel methods within the field of tissue engineering for the development of a bio-artificial, cell-based hormone replacement therapy that may minimize the need of IS. To support this, it is necessary to develop/optimize novel/smart/safe biomaterials, scaffolds, bio-matrices and bio-barriers that may protect grafted cells from immune rejection and simultaneously promote appropriate vascularization/innervation with an efficient exchange of nutrients to optimize cellular long-term survival and proper function.  It is also necessary to investigate methods to use different cell sources including human progenitor cells and induced pluripotent stem cells as a valid option for cell replacement therapy. 

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

This Funding Opportunity Announcement (FOA) is dedicated to the discovery of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.  It supports the optimization of therapeutic lead(s) showing convincing proof-of-concept.   At the end of the funding period, projects that successfully advance through support from this program will have identified a optimized candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE Bio Development track for further development to enable filing for an Investigational New Drug (IND).   

The Group Foundation for Advancing Mental Health is dedicated to changing lives by advancing the most effective and innovative approaches to group therapy education, training, research, and community outreach. To that end, the foundation is seeking research-focused applications to support group psychotherapy research that focuses on one of five clinical populations: children, the elderly, the chronically mentally ill, substance abusers, and/or significantly ill patients with marked functional impairment.

Cameroon is one of the 30 countries with the highest burden of TB/HIV co-infection worldwide. Only 54% of TB cases were notified in 2016 and 5.5% were children. TB treatment coverage was 55% and treatment success 84%.Despite implementation of TB and HIV strategic plans, TB case finding, diagnosis, and management remain suboptimal. TB/HIV co-infection remains high, Isoniazid Preventive Therapy (IPT) implementation is limited, and antiretroviral therapy (ART) services are not fully integrated in TB clinics. Human resource capacity is limited, and there are continued challenges with stock management.Cameroon adheres to the Sustainable Development Goals and the WHO Strategy to END TB. This NOFO will support development of models to improve screening, case identification, prevention, diagnosis, and treatment of TB among people living with HIV (PLHIV). It will also strengthen HIV testing, ART initiation, clinical monitoring, and care for TB clients, and strengthen health systems by building monitoring and evaluation (M&E) and infection control (IC) capacity. These interventions will strengthen TB/HIV services and improve capacity for an effective TB/HIV response in Cameroon.

The Foundation for Physical Therapy Research is dedicated to improving the quality and delivery of patient care by providing support for scientifically based and clinically relevant research related to the effectiveness of physical therapist practice. To that end, the foundation is accepting Letters of Intent for its Magistro Family Research Grant. Through the program, grants of up to $100,000 will be awarded to research projects focused on evaluating the effectiveness of interventions most commonly delivered by physical therapists, as determined by current practice standards, as well as those focused on the development of innovative physical therapist interventions. Priority will be given to studies that examine not only the therapeutic effectiveness of interventions but also their cost effectiveness. FPTR supports only studies in which the interventions are provided by physical therapists or select components of the intervention are provided by physical therapist assistants under the direction and supervision of physical therapists.

This is the renewal of a Funding Opportunity Announcement (FOA), issued by NICHD, NINDS, NIBIB, NIDCD, and NINR, National Institutes of Health, to invite grant applications from institutions/organizations that propose to build a research infrastructure center to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research centers that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that are particularly relevant to medical rehabilitation research and the needs of people with chronic physical disabilities. Specifically, the NIH is interested in addressing gaps in the rehabilitation research portfolio and is particularly interested in the following high-priority areas: pediatric rehabilitation; personalized medicine approaches; family, caregiver, and community support; implementation and dissemination research; clinical trial design and combinatorial therapies; strategies to explore and validate combination therapies; and, technology to track real-world outcomes.

The Foundation, like the physical therapy profession, is dedicated to the goal of improving the quality and delivery of patient care. The Foundation accomplishes this by providing support to emerging investigators to promote scientifically based and clinically relevant research related to the effectiveness of physical therapist practice. The Foundation supports research projects in any specialty. The Foundation supports only those intervention studies in which the interventions are provided by physical therapists, or selected components of the interventions are provided by physical therapist assistants under the direction and supervision of physical therapists.

The Michael J. Fox Foundation will award one-to-two-year grants to test non-pharmacological interventions for the treatment of gait and balance disturbances in people with Parkinson's disease (PD). We are particularly interested in proof-of-concept, validation and data-analysis projects. This program seeks proposals for research studying the therapeutic benefit of: Assistive devices (e.g., back or leg braces). Novel technologies (e.g., laser or wearable devices). Rehabilitative therapy programs (e.g., occupational or physical therapy)

The Foundation for Physical Therapy Research is dedicated to improving the quality and delivery of patient care by providing support for scientifically based and clinically relevant research related to the effectiveness of physical therapist practice. To that end, the foundation is accepting Letters of Intent for its Magistro Family Research Grant. Through the program, grants of up to $100,000 will be awarded to research projects focused on evaluating the effectiveness of interventions most commonly delivered by physical therapists, as determined by current practice standards, as well as those focused on the development of innovative physical therapist interventions. Priority will be given to studies that examine not only the therapeutic effectiveness of interventions but also their cost effectiveness. FPTR supports only studies in which the interventions are provided by physical therapists or select components of the intervention are provided by physical therapist assistants under the direction and supervision of physical therapists.

This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct an annual intensive workshop/conference/meeting that addresses the needs of early stage HIV/AIDS researchers utilizing nonhuman primates (NHPs) as they translate preclinical research from NHPs to human clinical trials. The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/milestone-driven projects. Conference topics should also include other considerations such as statistical and host genetics considerations; methods to translate the results of NHP studies to clinical trials in humans; and how to develop new NHP research programs to better reflect clinical observations and findings in human HIV/AIDS patients.

The Lung Cancer Research Foundation's pilot grant program provides funding for innovative research focused on the prevention, diagnosis, treatment, and cure of lung cancer. Grants of up to $150,000 over two years will be awarded in support of projects in one or more of the following areas of lung cancer research: lung cancer biology; prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; development of more effective and less toxic therapies; supportive measures for people with lung cancer and their families; and quality of care and outcomes research.

The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression.